Fol. Biol. 2016, 62, 258-262

https://doi.org/10.14712/fb2016062060258

Comparison of Plasma Osteopontin Levels between Patients with Borderline Ovarian Tumours and Serous Ovarian Carcinoma

Jan H. Živný1, S. Leahomschi2, P. Klener, Jr.1,3, J. Živný2, M. Haluzík4, D. Cibula2

1Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Czech Republic
2Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
31st Department of Medicine – Department of Haematology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic
4Institute of Medical Biochemistry and Laboratory Diagnostics, First Faculty of Medicine, Charles University and General University Hospital in Prague, Czech Republic

Received May 2016
Accepted June 2016

Crossref Cited-by Linking

  • Villanueva Francisco, Araya Hector, Briceño Pedro, Varela Nelson, Stevenson Andres, Jerez Sofia, Tempio Fabian, Chnaiderman Jonas, Perez Carola, Villarroel Milena, Concha Emma, Khani Farzaneh, Thaler Roman, Salazar\u2010Onfray Flavio, Stein Gary S, van Wijnen Andre J., Galindo Mario: The cancer\u2010related transcription factor RUNX2 modulates expression and secretion of the matricellular protein osteopontin in osteosarcoma cells to promote adhesion to endothelial pulmonary cells and lung metastasis. Journal Cellular Physiology 2019, 234, 13659. <https://doi.org/10.1002/jcp.28046>
  • Han Xingwen, Wang Wenji, He Jingjing, Jiang Lei, Li Xun: Osteopontin as a biomarker for osteosarcoma therapy and prognosis (Review). Oncol Lett 2019. <https://doi.org/10.3892/ol.2019.9905>
Crossref Cited-by Linking logo